Form 8-K - Current report:
SEC Accession No. 0001169245-23-000052
Filing Date
2023-10-03
Accepted
2023-10-03 07:17:19
Documents
12
Period of Report
2023-09-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K phas-20230927.htm   iXBRL 8-K 26734
  Complete submission text file 0001169245-23-000052.txt   158305

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT phas-20230927.xsd EX-101.SCH 1904
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT phas-20230927_lab.xml EX-101.LAB 25850
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT phas-20230927_pre.xml EX-101.PRE 13583
6 EXTRACTED XBRL INSTANCE DOCUMENT phas-20230927_htm.xml XML 2818
Mailing Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355
Business Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355 (610) 981-6500
PhaseBio Pharmaceuticals Inc (Filer) CIK: 0001169245 (see all company filings)

EIN.: 030375697 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38697 | Film No.: 231301549
SIC: 2834 Pharmaceutical Preparations